Maternal hemodynamic effects associated with intravenous and neuraxial dexmedetomidine during labor and cesarean delivery: a single center retrospective study (2021–2024)
Authors' conclusion
Our clinical experience demonstrated maternal adverse events that might be traced to the administration of either IV or neuraxial dexmedetomidine, which were more common after IV administration.
Study context
- Population
- Parturients receiving dexmedetomidine during labor and delivery (2022–2024)1,177 records reviewed
- Participants
- 1,100 participants
- Exposure
- Intravenous (IV) vs neuraxial dexmedetomidine
- Outcome
- Maternal adverse events related to dexmedetomidine administration
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Maternal adverse events (all routes)
Maternal heart rate abnormalities: 47 cases
6.1%
95% CI 4.5–8.0
Bradycardia: 16 cases
2.1%
95% CI 1.2–3.4
Hypotension: 57 cases
7.2%
95% CI 5.5–9.3
Sedation: 9 cases
1.2%
95% CI 0.6–2.3
Observational data: associations, not effects.
Further findings
Indications
- Most often for augmentation of cesarean anesthesia, breakthrough labor pain, and shivering
Original publication
Maternal hemodynamic effects associated with intravenous and neuraxial dexmedetomidine during labor and cesarean delivery: a single center retrospective study (2021–2024). Int J Obstet Anesth. Published 17 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →